BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17145955)

  • 1. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
    Pion M; Granelli-Piperno A; Mangeat B; Stalder R; Correa R; Steinman RM; Piguet V
    J Exp Med; 2006 Dec; 203(13):2887-93. PubMed ID: 17145955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.
    Stopak KS; Chiu YL; Kropp J; Grant RM; Greene WC
    J Biol Chem; 2007 Feb; 282(6):3539-46. PubMed ID: 17110377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Gag-virus-like particles inhibit HIV-1 replication in dendritic cells and T cells through IFN-α-dependent upregulation of APOBEC3G and 3F.
    Chang MO; Suzuki T; Yamamoto N; Watanabe M; Takaku H
    J Innate Immun; 2012; 4(5-6):579-90. PubMed ID: 22739040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
    Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
    J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of allogeneic in vitro stimulation and in vivo immunization on memory CD4(+) T-cell APOBEC3G expression and HIV-1 infectivity.
    Pido-Lopez J; Wang Y; Seidl T; Babaahmady K; Vaughan R; Lehner T
    Eur J Immunol; 2009 Jul; 39(7):1956-65. PubMed ID: 19585516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term passage of Vif-null HIV-1 in CD4
    Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
    Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.
    Amoêdo ND; Afonso AO; Cunha SM; Oliveira RH; Machado ES; Soares MA
    PLoS One; 2011; 6(8):e24118. PubMed ID: 21897871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    Wang X; Dolan PT; Dang Y; Zheng YH
    J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
    Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of Alu retrotransposition by APOBEC3G.
    Hulme AE; Bogerd HP; Cullen BR; Moran JV
    Gene; 2007 Apr; 390(1-2):199-205. PubMed ID: 17079095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    Soros VB; Yonemoto W; Greene WC
    PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.